Working DraftImpeachment Trial of Vice President Sara Duterte
← Timed transcript

Witness record

November 20, 2026

Witnesses called to the stand, with their most consequential testimony linked to the reviewed transcript and official hearing video.

Witnesses

Read and verify

Click a timestamp to cue the embedded source video. The adjacent turn ID opens the reviewed transcript in context.

01

Dr. Ceferino S. Rodolfo

Defense witness; DTI Undersecretary; BOI Vice Chairman and Managing Head

Rodolfo distinguished eligibility for incentives from actual use: CALE88 Foods Corporation used VAT zero rating in 2024 and 2026, covering 2023 and 2025 performance. It did not avail itself of an income-tax holiday; he said losses in its first two operating years made that holiday meaningless.

Rodolfo put CALE88 Foods Corporation’s reported 2023–2025 sales at ₱208,748,899. When Sen. Sherwin T. Gatchalian compared this with about ₱776 million in AMLC inward remittances, Rodolfo said the BOI submissions supplied no explanation for receipts exceeding declared sales. He put bank-certified remittances at US$721,283 and said BOI lacked bank certificates for 2024, when the company reported approximately ₱150 million in exports.

02

Pilar Marilyn M. Pagayunan

Defense witness; Director IV, Center for Food Regulation and Research, FDA

Pagayunan described deficiencies in CALE88 Foods Corporation’s initial banana-chip application and its revised label. She said the revised label removed the cardaba claim and provided complete nutrition facts supported by a laboratory test result. She explained that a certificate of analysis supported the nutrition declaration.

Prosecution counsel Atty. Reynaldo Robles stipulated that CALE88 Foods Corporation applied for two product registrations, for local manufacture and export, submitted appropriate requirements and received the certificates. Defense counsel Atty. Justin Nicol B. Gular added compliance with the requirements, which Robles accepted. Escudero later read this exchange back into the record.

Pagayunan said her office evaluated product safety and quality and identified the FDA Field Regulatory Operations Office as the unit handling inspections. Escudero sustained an objection to further questioning on whether products were actually manufactured or sold and in what quantities, explaining that she could not answer those questions.